Journey Medical Corporation (DERM) Q2 FY26 Earnings Call

Accelerating Mrosi prescriptions, improving reimbursement, and positive EBITDA are driving Journey Medical’s operating momentum.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-12
Length43 minutes
EPS$-0.01
EPS consensus$-0.01
Revenue$18.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26

All DERM earnings · Back to DERM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.